ABCL Stock Forecast 2025-2026
Distance to ABCL Price Targets
ABCL Price Momentum
10 Quality Stocks Worth Considering Now
Researching AbCellera (ABCL) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ABCL and similar high-potential opportunities.
Latest ABCL Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ABCL has a bullish consensus with a median price target of $9.00 (ranging from $5.00 to $28.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $2.60, the median forecast implies a 246.2% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tiago Fauth at Credit Suisse, projecting a 976.9% upside. Conversely, the most conservative target is provided by Scott Schoenhaus at Keybanc, suggesting a 92.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABCL Analyst Ratings
ABCL Price Target Range
Latest ABCL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABCL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $5.00 |
| Mar 3, 2025 | Benchmark | Robert Wasserman | Hold | Reiterates | $0.00 |
| Feb 28, 2025 | Stifel | Stephen Willey | Buy | Maintains | $10.00 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $4.00 |
| Nov 5, 2024 | Stifel | Stephen Willey | Buy | Reiterates | $12.00 |
| Nov 5, 2024 | Benchmark | Robert Wasserman | Hold | Reiterates | $0.00 |
| Aug 20, 2024 | Benchmark | Robert Wasserman | Hold | Downgrade | $0.00 |
| Jul 11, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $5.00 |
| May 8, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $7.00 |
| Feb 22, 2024 | Benchmark | Robert Wasserman | Buy | Upgrade | $0.00 |
| Feb 21, 2024 | Stifel | Stephen Willey | Buy | Maintains | $17.00 |
| Dec 5, 2023 | Keybanc | Scott Schoenhaus | Overweight | Initiates | $6.00 |
| Oct 13, 2023 | Piper Sandler | Allison Bratzel | Overweight | Assumes | $20.00 |
| Aug 31, 2023 | Benchmark | Robert Wasserman | Buy | Maintains | $12.00 |
| Aug 4, 2023 | Goldman Sachs | Andrea Tan | Buy | Maintains | $24.00 |
| May 5, 2023 | Credit Suisse | Tiago Fauth | Outperform | Maintains | $28.00 |
| Feb 28, 2023 | Cowen & Co. | Steven Mah | Outperform | Initiates | $0.00 |
| Feb 22, 2023 | Credit Suisse | Tiago Fauth | Outperform | Reiterates | $34.00 |
| Feb 22, 2023 | BMO Capital | Gary Nachman | Outperform | Maintains | $32.00 |
| Jan 6, 2023 | SVB Leerink | Puneet Souda | Outperform | Maintains | $18.00 |
AbCellera Biologics Inc. (ABCL) Competitors
The following stocks are similar to AbCellera based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AbCellera Biologics Inc. (ABCL) Financial Data
AbCellera Biologics Inc. has a market capitalization of $753.91M with a P/E ratio of -4.7x. The company generates $28.83M in trailing twelve-month revenue with a 100.0% profit margin.
Revenue growth is -45.0% quarter-over-quarter, while maintaining an operating margin of -807.0% and return on equity of -14.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
AbCellera Biologics Inc. (ABCL) Business Model
About AbCellera Biologics Inc.
Develops antibody therapies through innovative technology.
AbCellera Biologics collaborates with pharmaceutical and biotechnology companies to develop antibody-based treatments. It generates revenue by leveraging its advanced technology platform for high-throughput screening, microfluidics, and bioinformatics, which accelerates the discovery of therapeutic antibodies.
Founded in 2012 and based in Vancouver, Canada, AbCellera is focused on personalized medicine and tackling complex diseases like cancer and infections. Its strategic partnerships with leading biotech firms enhance its role in the biotechnology market, addressing unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
596
CEO
Dr. Carl L.G. Hansen Ph.D.
Country
Canada
IPO Year
2020
Website
www.abcellera.comAbCellera Biologics Inc. (ABCL) Latest News & Analysis
Latest News
AbCellera will participate in investor conferences scheduled for May and June 2023.
AbCellera's participation in investor conferences signals potential growth opportunities and increased visibility, which may attract investor interest and impact stock performance.
AbCellera (ABCL) will release its Q1 2025 financial results on May 8, 2025.
AbCellera's upcoming Q1 2025 financial results may indicate growth potential or challenges, influencing investor sentiment and stock performance.
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
30 days agoAbCellera will present in vivo data on PSMA x CD3 T-Cell Engagers at the AACR 2025 conference, highlighting potential advancements in cancer treatment.
AbCellera's presentation of in vivo data on PSMA x CD3 T-Cell Engagers could indicate progress in cancer treatment, potentially affecting stock performance and market interest.
AbCellera Biologics Inc. (NASDAQ:ABCL) will hold its Q4 2024 Earnings Conference Call on February 27, 2025, at 5:00 PM ET, featuring key executives and analysts.
AbCellera's Q4 2024 earnings call provides insights into financial performance and strategic direction, influencing investor sentiment and future stock valuation.
AbCellera announced its full year 2024 business results, providing updates on its financial performance and operational developments.
AbCellera's full year 2024 results may impact stock performance, indicating financial health, growth potential, and future investment opportunities for shareholders.
AbCellera Biologics Inc. (ABCL) reported a quarterly loss of $0.11 per share, better than the expected loss of $0.15, and improved from a loss of $0.17 per share a year earlier.
AbCellera's smaller-than-expected quarterly loss indicates improving performance, potentially boosting investor confidence and affecting stock valuation positively.
Frequently Asked Questions About ABCL Stock
What is AbCellera Biologics Inc.'s (ABCL) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, AbCellera Biologics Inc. (ABCL) has a median price target of $9.00. The highest price target is $28.00 and the lowest is $5.00.
Is ABCL stock a good investment in 2025?
According to current analyst ratings, ABCL has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABCL stock?
Wall Street analysts predict ABCL stock could reach $9.00 in the next 12 months. This represents a 246.2% increase from the current price of $2.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AbCellera Biologics Inc.'s business model?
AbCellera Biologics collaborates with pharmaceutical and biotechnology companies to develop antibody-based treatments. It generates revenue by leveraging its advanced technology platform for high-throughput screening, microfluidics, and bioinformatics, which accelerates the discovery of therapeutic antibodies.
What is the highest forecasted price for ABCL AbCellera Biologics Inc.?
The highest price target for ABCL is $28.00 from Tiago Fauth at Credit Suisse, which represents a 976.9% increase from the current price of $2.60.
What is the lowest forecasted price for ABCL AbCellera Biologics Inc.?
The lowest price target for ABCL is $5.00 from Scott Schoenhaus at Keybanc, which represents a 92.3% increase from the current price of $2.60.
What is the overall ABCL consensus from analysts for AbCellera Biologics Inc.?
The overall analyst consensus for ABCL is bullish. Out of 12 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are ABCL stock price projections?
Stock price projections, including those for AbCellera Biologics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.